Cytotheryx was selected out of many excellent proposals as one of eight recipients that have been awarded funding in 2021 by Regenerative Medicine Minnesota (RMM). In response, Dr. Robert Kaiser, Chief Operating Officer at Cytotheryx, shared: “Cytotheryx is honored to have our research recognized by Regenerative Medicine Minnesota in the awarding of this prestigious grant. As our team at Cytotheryx works to address unmet needs for patients with liver-related disease by providing a consistent, high-quality source of primary human hepatocytes, the support of Regenerative Medicine Minnesota is enabling our focused innovation to help get our products to patients.”

Regenerative Medicine Minnesota aims to improve the health of Minnesotans by advancing regenerative medicine. This state-wide initiative opens new economic opportunities through commercialization of technologies and leverages the strengths of Minnesota institutions to position the state at the forefront of regenerative medicine. Learn more about RMM on their website.